Lori Dwyer
Adult Health · Philadelphia, PANPI 1770604282
Payments from drug & device makers
Across 300 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$991
- Novo Nordisk$814
- Amgen$543
- AstraZeneca$500
- Pfizer$364
- Astellas Pharma US Inc$353
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $991 |
| Novo Nordisk | 40 | $814 |
| Amgen | 47 | $543 |
| AstraZeneca(2 entities) | 28 | $500 |
| Pfizer | 24 | $364 |
| Astellas Pharma US Inc | 15 | $353 |
| Abbott | 12 | $270 |
| Exact Sciences | 13 | $252 |
| Boehringer Ingelheim | 10 | $205 |
| Lilly USA, LLC | 8 | $171 |
| GSK | 8 | $159 |
| Merck | 5 | $76 |
| Shield Therapeutics Inc | 3 | $64 |
| Lundbeck LLC | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Novartis | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Boston Scientific | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $20 |
| Krystal Biotech Inc | 1 | $20 |
How this compares
$5,129 in reported general payments places this provider in the 90th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $93,217 |
| JardianceEmpagliflozin | 74 | $68,778 |
| OzempicSemaglutide | 59 | $57,275 |
| FarxigaDapagliflozin Propanediol | 68 | $51,347 |
| TrulicityDulaglutide | 52 | $47,997 |
| XareltoRivaroxaban | 53 | $38,486 |
| EntrestoSacubitril/Valsartan | 33 | $26,077 |
| LinzessLinaclotide | 30 | $25,710 |
| JanuviaSitagliptin Phosphate | 15 | $22,639 |
| Repatha SureclickEvolocumab | 24 | $15,285 |
| MyrbetriqMirabegron | 25 | $12,549 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $9,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,102 |
| Atorvastatin Calcium | 577 | $7,780 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 267 | $7,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $364 | $93,217113 claims |
| Boehringer IngelheimJardiance | $205 | $68,77874 claims |
| Novo NordiskOzempic | $814 | $57,27559 claims |
| AstraZenecaFarxiga, Symbicort | $500 | $53,55979 claims |
| Lilly USA, LLCTrulicity | $171 | $47,99752 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $159 | $31,87273 claims |
| NovartisEntresto | $41 | $26,07733 claims |
| AbbVieLinzess | $991 | $25,71030 claims |
| MerckJanuvia | $76 | $22,63915 claims |
| Astellas Pharma US IncMyrbetriq | $353 | $12,54925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Philadelphia
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Abigail SmithPhiladelphia$302K
- Lauren MassimoPhiladelphia$139K
- Catherine HoldsworthPhiladelphia$64K
- Kevin CarneyPhiladelphia$53K
- Christine ChmielewskiPhiladelphia$52K
- Barbara RogersPhiladelphia$51K
- Joyce RossPhiladelphia$39K
- Veronica RichardsonPhiladelphia$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.